G E Bigelow
Overview
Explore the profile of G E Bigelow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
3521
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Strain E, Harrison J, Bigelow G
Clin Pharmacol Ther
. 2011 Jan;
89(3):443-9.
PMID: 21270789
A sublingual soluble-film formulation of buprenorphine/naloxone (B/N) has been approved by the US Food and Drug Administration for the treatment of opioid dependency. This preparation provides unit-dose, child-resistant packaging amenable...
2.
Walsh S, Chausmer A, Strain E, Bigelow G
Psychopharmacology (Berl)
. 2007 Oct;
196(1):143-55.
PMID: 17909753
Rationale: Butorphanol exerts activity at mu, kappa, and delta opiate receptors in rats and monkeys but produces predominant mu-like effects in humans. Objectives: The aim of this study was to...
3.
Evans S, Walsh S, Levin F, Foltin R, FISCHMAN M, Bigelow G
Drug Alcohol Depend
. 2001 Oct;
64(3):271-83.
PMID: 11672942
The effects of oral flupenthixol and intramuscular (i.m.) flupenthixol decanoate in combination with intravenous (i.v.) cocaine were evaluated in male cocaine abusers. Participants resided at an inpatient research unit for...
4.
Lin S, Moody D, Bigelow G, Foltz R
J Anal Toxicol
. 2001 Oct;
25(7):497-503.
PMID: 11599591
In order to support studies on various medication protocols for the treatment of cocaine abuse, an accurate, precise, and sensitive (2.5 to 750 ng/mL) liquid chromatography-tandem mass spectrometry assay was...
5.
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
Walsh S, Strain E, Abreu M, Bigelow G
Psychopharmacology (Berl)
. 2001 Oct;
157(2):151-62.
PMID: 11594439
Rationale: The availability of the highly selective and specific kappa opioid agonist enadoline provides an opportunity to explore the function of kappa receptors in humans and their potential utility as...
6.
Walsh S, Strain E, Bigelow G
J Pharmacol Exp Ther
. 2001 Sep;
299(1):147-58.
PMID: 11561074
Preclinical studies have demonstrated that kappa-opioid agonists can attenuate the neurochemical and behavioral effects of cocaine that are related to its reinforcing efficacy, suggesting that kappa-agonists may serve as pharmacotherapies...
7.
Dallery J, Silverman K, Chutuape M, Bigelow G, Stitzer M
Exp Clin Psychopharmacol
. 2001 Sep;
9(3):317-25.
PMID: 11534542
The study tested a voucher-based abstinence reinforcement procedure for reducing opiate and cocaine use in a population of treatment-resistant opiate- and cocaine-abusing methadone patients. Vouchers exchangeable for goods and services...
8.
Silverman K, Svikis D, Robles E, Stitzer M, Bigelow G
Exp Clin Psychopharmacol
. 2001 Aug;
9(1):14-23.
PMID: 11519628
This study evaluated a novel drug abuse treatment, the Therapeutic Workplace. In this treatment, patients are paid to perform jobs or to participate in job training. Salary is linked to...
9.
Becker A, Strain E, Bigelow G, Stitzer M, Johnson R
Am J Addict
. 2001 Jul;
10(2):111-21.
PMID: 11444154
This paper describes the time course of withdrawal and relapse in opioid-dependent volunteers (n = 8) who completed a gradual outpatient buprenorphine dose taper (28 days). Compliance with treatment was...
10.
Donny E, Bigelow G, Walsh S
Psychopharmacology (Berl)
. 2001 Jul;
155(4):338-47.
PMID: 11441423
Rationale: Dopaminergic compounds have been targeted as potential treatments for cocaine abuse because of the known role of dopamine systems in drug reinforcement. Recent preclinical and human data have focused...